19 results on '"Prados de la Torre, Esther"'
Search Results
2. Sustained seropositivity up to 20.5 months after COVID-19
- Author
-
Dobaño, Carlota, Ramírez-Morros, Anna, Alonso, Selena, Rubio, Rocío, Ruiz-Olalla, Gemma, Vidal-Alaball, Josep, Macià, Dídac, Catalina, Queralt Miró, Vidal, Marta, Casanovas, Aina Fuster, Prados de la Torre, Esther, Barrios, Diana, Jiménez, Alfons, Zanoncello, Jasmina, Melero, Natalia Rodrigo, Carolis, Carlo, Izquierdo, Luis, Aguilar, Ruth, Moncunill, Gemma, and Ruiz-Comellas, Anna
- Published
- 2022
- Full Text
- View/download PDF
3. Identifying prognostic gene panels in acute myeloid leukemia
- Author
-
Sanchez-Garcia, Joaquin, primary, Serrano, Josefina, additional, Prados de La Torre, Esther, additional, Serrano-López, Juana, additional, Aparicio-Perez, Clara, additional, Barragán, E, additional, and Montesinos, Pau, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Evolving Risk Classifications in AML in a Real-Life Scenario: After Changes upon Changes, Is It More and More Adverse?
- Author
-
Aparicio-Pérez, Clara, primary, Prados de la Torre, Esther, additional, Sanchez-Garcia, Joaquin, additional, Martín-Calvo, Carmen, additional, Martínez-Losada, Carmen, additional, Casaño-Sanchez, Javier, additional, Serrano-López, Juana, additional, and Serrano, Josefina, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Supplementary material. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
- Author
-
Pérez-Simón, José A. [0000-0003-3616-6101], Rodríguez-Arbolí, Eduardo [0000-0002-2237-6733], Ayala Bueno, Rosa [0000-0002-7902-2784], Montesinos, Pau [montesinos_pau@gva.es], Sargas, Claudia, Ayala Bueno, Rosa, Larráyoz, María José, Chillón, M. del Carmen, Rodríguez-Arbolí, Eduardo, Bilbao, Cristina, Prados de la Torre, Esther, Martínez-Cuadrón, David, Rodríguez-Veiga, Rebeca, Boluda, Blanca, Gil, Cristina, Bernal, T., Bergua, Juan, Algarra, Lorenzo, Tormo, Mar, Martínez-Sánchez, Pilar, Soria, Elena, Alonso-Domínguez, Juan Manuel, García, Raimundo, Amigo, María Luz, Herrera-Puente, Pilar, Sayas, María-José, Lavilla, Esperanza, Martínez-López, Joaquín, Calasanz, Mª Jose, García-Sanz, Ramón, Pérez-Simón, José A., Gómez Casares, María T., Sanchez-Garcia, Joaquin, Barragán, Eva, Montesinos, Pau, Pérez-Simón, José A. [0000-0003-3616-6101], Rodríguez-Arbolí, Eduardo [0000-0002-2237-6733], Ayala Bueno, Rosa [0000-0002-7902-2784], Montesinos, Pau [montesinos_pau@gva.es], Sargas, Claudia, Ayala Bueno, Rosa, Larráyoz, María José, Chillón, M. del Carmen, Rodríguez-Arbolí, Eduardo, Bilbao, Cristina, Prados de la Torre, Esther, Martínez-Cuadrón, David, Rodríguez-Veiga, Rebeca, Boluda, Blanca, Gil, Cristina, Bernal, T., Bergua, Juan, Algarra, Lorenzo, Tormo, Mar, Martínez-Sánchez, Pilar, Soria, Elena, Alonso-Domínguez, Juan Manuel, García, Raimundo, Amigo, María Luz, Herrera-Puente, Pilar, Sayas, María-José, Lavilla, Esperanza, Martínez-López, Joaquín, Calasanz, Mª Jose, García-Sanz, Ramón, Pérez-Simón, José A., Gómez Casares, María T., Sanchez-Garcia, Joaquin, Barragán, Eva, and Montesinos, Pau
- Abstract
Outcomes according to 2017 and 2022 ELN risk in intensively treated patients. Risk of death according to 2017 and 2022 ELN risk in intensively treated patients. Appendix A: Institutions and clinicians participating in the PETHEMA epidemiologic registry of acute myeloid leukemia and acute promyelocytic leukemia.
- Published
- 2023
6. Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry
- Author
-
Ministerio de Economía y Competitividad (España), Bristol-Myers Squibb, Instituto de Salud Carlos III, Sargas, Claudia, Ayala Bueno, Rosa, Larráyoz, María José, Chillón, M. del Carmen, Carrillo Cruz, Estrella, Bilbao, Cristina, Prados de la Torre, Esther, Martínez-Cuadrón, David, Rodríguez-Veiga, Rebeca, Boluda, Blanca, Gil, Cristina, Bernal, Teresa, Bergua, Juan, Algarra, Lorenzo, Tormo, Mar, Martínez-Sánchez, Pilar, Soria, Elena, Serrano, Josefina, Alonso-Domínguez, Juan Manuel, García-Boyero, Raimundo, Amigo, María Luz, Herrera-Puente, Pilar, Sayas, María-José, Lavilla, Esperanza, Martínez-López, Joaquín, Calasanz, Mª Jose, García-Sanz, Ramón, Pérez-Simón, José A., Gómez-Casares, M. T., Sanchez-Garcia, Joaquin, Barragán, Eva, Montesinos, Pau, Ministerio de Economía y Competitividad (España), Bristol-Myers Squibb, Instituto de Salud Carlos III, Sargas, Claudia, Ayala Bueno, Rosa, Larráyoz, María José, Chillón, M. del Carmen, Carrillo Cruz, Estrella, Bilbao, Cristina, Prados de la Torre, Esther, Martínez-Cuadrón, David, Rodríguez-Veiga, Rebeca, Boluda, Blanca, Gil, Cristina, Bernal, Teresa, Bergua, Juan, Algarra, Lorenzo, Tormo, Mar, Martínez-Sánchez, Pilar, Soria, Elena, Serrano, Josefina, Alonso-Domínguez, Juan Manuel, García-Boyero, Raimundo, Amigo, María Luz, Herrera-Puente, Pilar, Sayas, María-José, Lavilla, Esperanza, Martínez-López, Joaquín, Calasanz, Mª Jose, García-Sanz, Ramón, Pérez-Simón, José A., Gómez-Casares, M. T., Sanchez-Garcia, Joaquin, Barragán, Eva, and Montesinos, Pau
- Abstract
Next–Generation Sequencing (NGS) implementation to perform accurate diagnosis in acute myeloid leukemia (AML) represents a major challenge for molecular laboratories in terms of specialization, standardization, costs and logistical support. In this context, the PETHEMA cooperative group has established the first nationwide diagnostic network of seven reference laboratories to provide standardized NGS studies for AML patients. Cross–validation (CV) rounds are regularly performed to ensure the quality of NGS studies and to keep updated clinically relevant genes recommended for NGS study. The molecular characterization of 2856 samples (1631 derived from the NGS–AML project; NCT03311815) with standardized NGS of consensus genes (ABL1, ASXL1, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NPM1, NRAS, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, U2AF1 and WT1) showed 97% of patients having at least one mutation. The mutational profile was highly variable according to moment of disease, age and sex, and several co–occurring and exclusion relations were detected. Molecular testing based on NGS allowed accurate diagnosis and reliable prognosis stratification of 954 AML patients according to new genomic classification proposed by Tazi et al. Novel molecular subgroups, such as mutated WT1 and mutations in at least two myelodysplasia–related genes, have been associated with an adverse prognosis in our cohort. In this way, the PETHEMA cooperative group efficiently provides an extensive molecular characterization for AML diagnosis and risk stratification, ensuring technical quality and equity in access to NGS studies.
- Published
- 2023
7. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
- Author
-
Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Sargas, Claudia, Ayala Bueno, Rosa, Larráyoz, María José, Chillón, M. del Carmen, Rodríguez-Arbolí, Eduardo, Bilbao, Cristina, Prados de la Torre, Esther, Martínez-Cuadrón, David, Rodríguez-Veiga, Rebeca, Boluda, Blanca, Gil, Cristina, Bernal, T., Bergua, Juan, Algarra, Lorenzo, Tormo, Mar, Martínez-Sánchez, Pilar, Soria, Elena, Alonso-Domínguez, Juan Manuel, García, Raimundo, Amigo, María Luz, Herrera-Puente, Pilar, Sayas, María-José, Lavilla, Esperanza, Martínez-López, Joaquín, Calasanz, Mª Jose, García-Sanz, Ramón, Pérez-Simón, José A., Gómez Casares, María T., Sanchez-Garcia, Joaquin, Barragán, Eva, Montesinos, Pau, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, Sargas, Claudia, Ayala Bueno, Rosa, Larráyoz, María José, Chillón, M. del Carmen, Rodríguez-Arbolí, Eduardo, Bilbao, Cristina, Prados de la Torre, Esther, Martínez-Cuadrón, David, Rodríguez-Veiga, Rebeca, Boluda, Blanca, Gil, Cristina, Bernal, T., Bergua, Juan, Algarra, Lorenzo, Tormo, Mar, Martínez-Sánchez, Pilar, Soria, Elena, Alonso-Domínguez, Juan Manuel, García, Raimundo, Amigo, María Luz, Herrera-Puente, Pilar, Sayas, María-José, Lavilla, Esperanza, Martínez-López, Joaquín, Calasanz, Mª Jose, García-Sanz, Ramón, Pérez-Simón, José A., Gómez Casares, María T., Sanchez-Garcia, Joaquin, Barragán, Eva, and Montesinos, Pau
- Abstract
Next-Generation Sequencing is needed for the accurate genetic risk stratification of acute myeloid leukemia according to European LeukemiaNet (ELN) guidelines. We validated and compared the 2022 ELN risk classification in a real-life cohort of 546 intensively and 379 non-intensively treated patients. Among fit patients, those aged ≥65 years old showed worse OS than younger regardless risk classification. Compared with the 2017 classification, 14.5% of fit patients changed the risk with the 2022 classification, increasing the high-risk group from 44.3% to 51.8%. 3.7% and 0.9% FLT3-ITD mutated patients were removed from the favorable and adverse 2017 categories respectively to 2022 intermediate risk group. We suggest that midostaurin therapy could be a predictor for 3 years OS (85.2% with vs. 54.8% without midostaurin, P = 0.04). Forty-seven (8.6%) patients from the 2017 intermediate group were assigned to the 2022 adverse-risk group as they harbored myelodysplasia (MDS)-related mutations. Patients with one MDS-related mutation did not reach median OS, while patients with ≥2 mutations had 13.6 months median OS (P = 0.002). Patients with TP53 ± complex karyotype or inv(3) had a dismal prognosis (7.1 months median OS). We validate the prognostic utility of the 2022 ELN classification in a real-life setting providing supportive evidences to improve risk stratification guidelines.
- Published
- 2023
8. Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
- Author
-
Boluda, Blanca, primary, Sargas, Claudia, additional, Ayala, Rosa, additional, Larrayoz, Maria Jose, additional, Chillón Santos, María Carmen, additional, Carrillo-Cruz, Estrella, additional, Bilbao, Cristina, additional, Prados de La Torre, Esther, additional, Navarro-Vicente, Irene, additional, Martinez-Cuadron, David, additional, Rodríguez-Veiga, Rebeca, additional, Gil, Cristina, additional, Bernal del Castillo, Teresa, additional, Bergua Burgués, Juan Miguel, additional, Algarra, Lorenzo, additional, Tormo, Mar, additional, Martinez Sanchez, Pilar, additional, Soria, Elena, additional, Serrano, Josefina, additional, Alonso Dominguez, Juan Manuel, additional, García-Boyero, Raimundo, additional, Amigo, Maria Luz, additional, Herrera, Pilar, additional, Sayas, Maria Jose, additional, Lavilla, Esperanza, additional, Martínez-López, Joaquín, additional, Calasanz, María José, additional, García-Sanz, Ramón, additional, Perez-Simon, Jose A., additional, Gómez-Casares, María Teresa, additional, Sánchez-Garcia, Joaquín, additional, Barragán, Eva, additional, and Montesinos, Pau, additional
- Published
- 2022
- Full Text
- View/download PDF
9. Real-Life Comparative Analysis of Prognostic Risk Classification According to ELN 2010, 2017 and 2022 in AML Patients
- Author
-
Aparicio Pérez, Clara, primary, Gonzalez Teomiro, Ana Camila, additional, Martinez Losada, Maria Carmen, additional, Yébenes Ramírez, Manuel, additional, Martin Calvo, Carmen, additional, Prados de La Torre, Esther, additional, Sánchez-Garcia, Joaquín, additional, and Serrano, Josefina, additional
- Published
- 2022
- Full Text
- View/download PDF
10. Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
- Author
-
Sargas, Claudia, primary, Ayala, Rosa, additional, Larrayoz, Maria Jose, additional, Chillon, Carmen, additional, Carrillo, Estrella, additional, Bilbao, Cristina, additional, Prados de La Torre, Esther, additional, Martinez-Cuadron, David, additional, Rodríguez-Veiga, Rebeca, additional, Gil, Cristina, additional, Bernal, Teresa, additional, Bergua Burgués, Juan Miguel, additional, Algarra, Lorenzo, additional, Tormo, Mar, additional, Martínez Sánchez, Pilar, additional, Soria, Elena, additional, Serrano, Josefina, additional, Alonso Dominguez, Juan Manuel, additional, García-Boyero, Raimundo, additional, Amigo, Maria Luz, additional, Herrera, Pilar, additional, Sayas, María J., additional, Lavilla, Esperanza, additional, Martínez-López, Joaquín, additional, Calasanz, María José, additional, García-Sanz, Ramón, additional, Perez-Simon, Jose A., additional, Gómez-Casares, María Teresa, additional, Sánchez-Garcia, Joaquín, additional, Barragán, Eva, additional, and Montesinos, Pau, additional
- Published
- 2022
- Full Text
- View/download PDF
11. SARS-CoV-2 Seroprevalence Study in Pediatric Patients and Health Care Workers Using Multiplex Antibody Immunoassays
- Author
-
Prados de la Torre, Esther, Obando Santaella, Ignacio, Vidal, Marta, Felipe, Beatriz de, Aguilar, Ruth, Izquierdo, Luis, Olbrich, Peter, Dobaño, Carlota, Universidad de Sevilla. Departamento de Farmacología, Pediatría y Radiología, Junta de Andalucía, Universidad de Córdoba, European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER), Ministerio de Ciencia e Innovación. Programa 'Centro de Excelencia Severo Ochoa 2019-2023', and Generalitat de Catalunya. Programa CERCA
- Subjects
antigen ,children ,SARS-CoV-2 ,seropositivity ,healthcare workers ,antibody ,COVID-19 ,cohort ,PIMS-TS - Abstract
SARS-CoV-2 infection has become a global health problem specially exacerbated with the continuous appearance of new variants. Healthcare workers (HCW) have been one of the most affected sectors. Children have also been affected, and although infection generally presents as a mild disease, some have developed the Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS). We recruited 190 adults (HCW and cohabitants, April to June 2020) and 57 children (April 2020 to September 2021), of whom 12 developed PIMS-TS, in a hospital-based study in Spain. Using an in-house Luminex assay previously validated, antibody levels were measured against different spike and nucleocapsid SARS-CoV-2 proteins, including the receptor-binding domain (RBD) of the Alpha, Beta, Gamma, and Delta variants of concern (VoC). Seropositivity rates obtained from children and adults, respectively, were: 49.1% and 11% for IgG, 45.6% and 5.8% for IgA, and 35.1% and 7.3% for IgM. Higher antibody levels were detected in children who developed PIMS-TS compared to those who did not. Using the COVID-19 IgM/IgA ELISA (Vircell, S.L.) kit, widely implemented in Spanish hospitals, a high number of false positives and lower seroprevalences compared with the Luminex estimates were found, indicating a significantly lower specificity and sensitivity. Comparison of antibody levels against RBD-Wuhan versus RBD-VoCs indicated that the strongest positive correlations for all three isotypes were with RBD-Alpha, while the lowest correlations were with RBD-Delta for IgG, RBD-Gamma for IgM, and RBD-Beta for IgA. This study highlights the differences in antibody levels between groups with different demographic and clinical characteristics, as well as reporting the IgG, IgM, and IgA response to RBD VoC circulating at the study period.
- Published
- 2022
12. SARS-CoV-2 Seroprevalence Study in Pediatric Patients and Health Care Workers Using Multiplex Antibody Immunoassays
- Author
-
Prados de la Torre, Esther, primary, Obando, Ignacio, additional, Vidal, Marta, additional, de Felipe, Beatriz, additional, Aguilar, Ruth, additional, Izquierdo, Luis, additional, Carolis, Carlo, additional, Olbrich, Peter, additional, Capilla-Miranda, Ana, additional, Serra, Pau, additional, Santamaria, Pere, additional, Blanco-Lobo, Pilar, additional, Moncunill, Gemma, additional, Rodríguez-Ortega, Manuel J., additional, and Dobaño, Carlota, additional
- Published
- 2022
- Full Text
- View/download PDF
13. Eleven‐month longitudinal study of antibodies in SARS‐CoV‐2 exposed and naïve primary health care workers upon COVID‐19 vaccination
- Author
-
Dobaño, Carlota, primary, Ramírez‐Morros, Anna, additional, Alonso, Selena, additional, Ruiz‐Olalla, Gemma, additional, Rubio, Rocío, additional, Vidal, Marta, additional, Prados de la Torre, Esther, additional, Jairoce, Chenjerai, additional, Mitchell, Robert A., additional, Barrios, Diana, additional, Jiménez, Alfons, additional, Rodrigo Melero, Natalia, additional, Carolis, Carlo, additional, Izquierdo, Luis, additional, Zanoncello, Jasmina, additional, Aguilar, Ruth, additional, Vidal‐Alaball, Josep, additional, Moncunill, Gemma, additional, and Ruiz‐Comellas, Anna, additional
- Published
- 2022
- Full Text
- View/download PDF
14. SARS-CoV-2 Seroprevalence Study in Pediatric Patients and Health Care Workers Using Multiplex Antibody Immunoassays
- Author
-
Universidad de Sevilla. Departamento de Farmacología, Pediatría y Radiología, Junta de Andalucía, Universidad de Córdoba, European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER), Ministerio de Ciencia e Innovación. Programa “Centro de Excelencia Severo Ochoa 2019-2023”, Generalitat de Catalunya. Programa CERCA, Prados de la Torre, Esther, Obando Santaella, Ignacio, Vidal, Marta, Felipe, Beatriz de, Aguilar, Ruth, Izquierdo, Luis, Olbrich, Peter, Dobaño, Carlota, Universidad de Sevilla. Departamento de Farmacología, Pediatría y Radiología, Junta de Andalucía, Universidad de Córdoba, European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER), Ministerio de Ciencia e Innovación. Programa “Centro de Excelencia Severo Ochoa 2019-2023”, Generalitat de Catalunya. Programa CERCA, Prados de la Torre, Esther, Obando Santaella, Ignacio, Vidal, Marta, Felipe, Beatriz de, Aguilar, Ruth, Izquierdo, Luis, Olbrich, Peter, and Dobaño, Carlota
- Abstract
SARS-CoV-2 infection has become a global health problem specially exacerbated with the continuous appearance of new variants. Healthcare workers (HCW) have been one of the most affected sectors. Children have also been affected, and although infection generally presents as a mild disease, some have developed the Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS). We recruited 190 adults (HCW and cohabitants, April to June 2020) and 57 children (April 2020 to September 2021), of whom 12 developed PIMS-TS, in a hospital-based study in Spain. Using an in-house Luminex assay previously validated, antibody levels were measured against different spike and nucleocapsid SARS-CoV-2 proteins, including the receptor-binding domain (RBD) of the Alpha, Beta, Gamma, and Delta variants of concern (VoC). Seropositivity rates obtained from children and adults, respectively, were: 49.1% and 11% for IgG, 45.6% and 5.8% for IgA, and 35.1% and 7.3% for IgM. Higher antibody levels were detected in children who developed PIMS-TS compared to those who did not. Using the COVID-19 IgM/IgA ELISA (Vircell, S.L.) kit, widely implemented in Spanish hospitals, a high number of false positives and lower seroprevalences compared with the Luminex estimates were found, indicating a significantly lower specificity and sensitivity. Comparison of antibody levels against RBD-Wuhan versus RBD-VoCs indicated that the strongest positive correlations for all three isotypes were with RBD-Alpha, while the lowest correlations were with RBD-Delta for IgG, RBD-Gamma for IgM, and RBD-Beta for IgA. This study highlights the differences in antibody levels between groups with different demographic and clinical characteristics, as well as reporting the IgG, IgM, and IgA response to RBD VoC circulating at the study period.
- Published
- 2022
15. SARS-CoV-2 Seroprevalence Study in Pediatric Patients and Health Care Workers Using Multiplex Antibody Immunoassays
- Author
-
Junta de Andalucía, Universidad de Córdoba (España), Ministerio de Ciencia e Innovación (España), Agencia Estatal de Investigación (España), Generalitat de Catalunya, Prados de la Torre, Esther, Obando, Ignacio, Vidal, Marta, Felipe, Beatriz de, Aguilar, Ruth, Izquierdo Faubel, Luis, Carolis, Carlo, Olbrich, Peter, Capilla-Miranda, Ana, Serra, Pau, Santamaria, Pere, Blanco Lobo, Pilar, Moncunill, Gemma, Rodríguez-Ortega, Manuel J., Dobaño, Carlota, Junta de Andalucía, Universidad de Córdoba (España), Ministerio de Ciencia e Innovación (España), Agencia Estatal de Investigación (España), Generalitat de Catalunya, Prados de la Torre, Esther, Obando, Ignacio, Vidal, Marta, Felipe, Beatriz de, Aguilar, Ruth, Izquierdo Faubel, Luis, Carolis, Carlo, Olbrich, Peter, Capilla-Miranda, Ana, Serra, Pau, Santamaria, Pere, Blanco Lobo, Pilar, Moncunill, Gemma, Rodríguez-Ortega, Manuel J., and Dobaño, Carlota
- Abstract
SARS-CoV-2 infection has become a global health problem specially exacerbated with the continuous appearance of new variants. Healthcare workers (HCW) have been one of the most affected sectors. Children have also been affected, and although infection generally presents as a mild disease, some have developed the Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS). We recruited 190 adults (HCW and cohabitants, April to June 2020) and 57 children (April 2020 to September 2021), of whom 12 developed PIMS-TS, in a hospital-based study in Spain. Using an in-house Luminex assay previously validated, antibody levels were measured against different spike and nucleocapsid SARS-CoV-2 proteins, including the receptor-binding domain (RBD) of the Alpha, Beta, Gamma, and Delta variants of concern (VoC). Seropositivity rates obtained from children and adults, respectively, were: 49.1% and 11% for IgG, 45.6% and 5.8% for IgA, and 35.1% and 7.3% for IgM. Higher antibody levels were detected in children who developed PIMS-TS compared to those who did not. Using the COVID-19 IgM/IgA ELISA (Vircell, S.L.) kit, widely implemented in Spanish hospitals, a high number of false positives and lower seroprevalences compared with the Luminex estimates were found, indicating a significantly lower specificity and sensitivity. Comparison of antibody levels against RBD-Wuhan versus RBD-VoCs indicated that the strongest positive correlations for all three isotypes were with RBD-Alpha, while the lowest correlations were with RBD-Delta for IgG, RBD-Gamma for IgM, and RBD-Beta for IgA. This study highlights the differences in antibody levels between groups with different demographic and clinical characteristics, as well as reporting the IgG, IgM, and IgA response to RBD VoC circulating at the study period.
- Published
- 2022
16. Additional file 1 of Sustained seropositivity up to 20.5 months after COVID-19
- Author
-
Dobaño, Carlota, Ramírez-Morros, Anna, Alonso, Selena, Rubio, Rocío, Ruiz-Olalla, Gemma, Vidal-Alaball, Josep, Macià, Dídac, Catalina, Queralt Miró, Vidal, Marta, Casanovas, Aina Fuster, Prados de la Torre, Esther, Barrios, Diana, Jiménez, Alfons, Zanoncello, Jasmina, Melero, Natalia Rodrigo, Carolis, Carlo, Izquierdo, Luis, Aguilar, Ruth, Moncunill, Gemma, and Ruiz-Comellas, Anna
- Abstract
Additional file 1: Table S1. Association of baseline variables and comorbidities with levels of SARS-CoV-2 antibodies at time point 4 (January-February 2021) prior to the massive rollout of vaccination. Table S2. Seropositivity against the SARS-CoV-2 receptor-binding domain antigen from variants of concern. Table S3. Reinfections. Table S4. Significant associations of baseline variables with differential antibody rate of change. Fig. S1. Overall distribution of antibody responses for each isotype and antigen pair of the 128 pre-pandemic samples (negative controls) along with the cutoffs.
- Published
- 2022
- Full Text
- View/download PDF
17. Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry
- Author
-
Sargas, Claudia, Ayala Díaz, Rosa María, Larráyoz, María José, Chillón, María Carmen, Carrillo Cruz, Estrella, Bilbao Sieyro, Cristina, Prados de la Torre, Esther, Martínez Cuadrón, David, Rodríguez Veiga, Rebeca, Boluda, Blanca, Gil, Cristina, Bernal, Teresa, Bergua, Juan Miguel, Algarra, Lorenzo, Tormo, Mar, Martínez Sánchez, Pilar, Soriano, Elena, Serrano, Josefina, Alonso Domínguez, Juan Manuel, García Boyero, Raimundo, Amigo, Maria Luz, Herrera Puente, Pilar, Sayas, María José, Lavilla Rubira, Esperanza, Martínez López, Joaquín, Calasanz, María José, García Sanz, Ramón, Pérez Simón, José Antonio, Gómez Casares, María Teresa, Sánchez García, Joaquín, Barragán, Eva, and Montesinos, Pau
- Subjects
Genética médica ,Cancer Research ,Oncology ,Medicina ,acute myeloid leukemia ,Next–Generation Sequencing ,cross–validations ,mutational profile ,genomic classification ,clinical validation ,Oncología - Abstract
Next–Generation Sequencing (NGS) implementation to perform accurate diagnosis in acute myeloid leukemia (AML) represents a major challenge for molecular laboratories in terms of specialization, standardization, costs and logistical support. In this context, the PETHEMA cooperative group has established the first nationwide diagnostic network of seven reference laboratories to provide standardized NGS studies for AML patients. Cross–validation (CV) rounds are regularly performed to ensure the quality of NGS studies and to keep updated clinically relevant genes recommended for NGS study. The molecular characterization of 2856 samples (1631 derived from the NGS–AML project; NCT03311815) with standardized NGS of consensus genes (ABL1, ASXL1, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NPM1, NRAS, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, U2AF1 and WT1) showed 97% of patients having at least one mutation. The mutational profile was highly variable according to moment of disease, age and sex, and several co–occurring and exclusion relations were detected. Molecular testing based on NGS allowed accurate diagnosis and reliable prognosis stratification of 954 AML patients according to new genomic classification proposed by Tazi et al. Novel molecular subgroups, such as mutated WT1 and mutations in at least two myelodysplasia–related genes, have been associated with an adverse prognosis in our cohort. In this way, the PETHEMA cooperative group efficiently provides an extensive molecular characterization for AML diagnosis and risk stratification, ensuring technical quality and equity in access to NGS studies.
- Published
- 2023
18. Proteomic and Bioinformatic Analysis of Streptococcus suis Human Isolates: Combined Prediction of Potential Vaccine Candidates
- Author
-
Prados de la Torre, Esther, primary, Rodríguez-Franco, Antonio, additional, and Rodríguez-Ortega, Manuel J., additional
- Published
- 2020
- Full Text
- View/download PDF
19. Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDHand NPM1Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
- Author
-
Boluda, Blanca, Sargas, Claudia, Ayala, Rosa, Larrayoz, Maria Jose, Chillón Santos, María Carmen, Carrillo-Cruz, Estrella, Bilbao, Cristina, Prados de La Torre, Esther, Navarro-Vicente, Irene, Martinez-Cuadron, David, Rodríguez-Veiga, Rebeca, Gil, Cristina, Bernal del Castillo, Teresa, Bergua Burgués, Juan Miguel, Algarra, Lorenzo, Tormo, Mar, Martinez Sanchez, Pilar, Soria, Elena, Serrano, Josefina, Alonso Dominguez, Juan Manuel, García-Boyero, Raimundo, Amigo, Maria Luz, Herrera, Pilar, Sayas, Maria Jose, Lavilla, Esperanza, Martínez-López, Joaquín, Calasanz, María José, García-Sanz, Ramón, Perez-Simon, Jose A., Gómez-Casares, María Teresa, Sánchez-Garcia, Joaquín, Barragán, Eva, and Montesinos, Pau
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.